Overall characteristics of patients with rheumatoid arthritis by EULAR response to rituximab at week 24 (W24)
| Overall population (n=115) | Good/moderate responders (n=92) | Non-responders (n=22) | |
| Women, n (%) | 92 (80.0) | 73 (79.3) | 18 (81.8) |
| Age, mean±SD | 55.50±11.15 | 55.47±11.33 | 55.77±10.84 |
| Rheumatoid arthritis duration (year), mean±SD | 14.06±9.29 | 14.07±9.55 | 14.25±8.54 |
| Anti-CCP-positive, n (%) | 93 (80.9) | 75 (81.5) | 17 (77.3) |
| RF positive, n (%) | 82 (71.3) | 68 (73.9) | 13 (59.1) |
| Prednisone users, n (%) | 87 (75.7) | 66 (71.7) | 20 (90.9) |
| Prednisone dosage (mg/day), mean±SD | 7.72±2.90 | 7.64±2.90 | 8.02±2.68 |
| DAS28-CRP, mean±SD | |||
| At initiation | 5.68±0.90 | 5.76±0.87 | 5.34±0.97 |
| At W24 | 3.94±1.07 | 3.63±0.84 | 5.23±0.98 |
| DAS28-CRP change at W24, mean±SD | −1.74±1.14 | −2.13±0.87 | −0.11±0.55 |
| BAFF level at RTX initiation (pg/μL), mean±SD | 588.34±364.51 | 590.89±368.23 | 475.8±50.20 |
DAS28-CRP, Disease Activity Score in 28 joints with C reactive protein; EULAR, European League Against Rheumatism; RF, rheumatoid factor; RTX, rituximab.